Frontier
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2021; 27(46): 7866-7893
Published online Dec 14, 2021. doi: 10.3748/wjg.v27.i46.7866
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande
Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande, Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence 50134, Italy
Author contributions: Calistri L, Rastrelli V and Colagrande S contributed equally to this work, in terms of conceptualization, writing the original draft, reviewing and editing; Maraghelli D, Vidali S, Pietragalla M contributed in figures and references research; and all the authors have read and approved the final manuscript.
Conflict-of-interest statement: There are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Stefano Colagrande, MD, Full Professor, Department of Experimental and Clinical Biomedical Sciences Mario Serio, University of Florence, Azienda Ospedaliera Universitaria Careggi, Largo Brambilla 3, Florence 50134, Italy. stefano.colagrande@unifi.it
Received: April 19, 2021
Peer-review started: April 19, 2021
First decision: June 3, 2021
Revised: June 15, 2021
Accepted: November 29, 2021
Article in press: November 29, 2021
Published online: December 14, 2021
Abstract

The liver is the major drug-metabolizing and drug-detoxifying organ. Many drugs can cause liver damage through various mechanisms; however, the liver response to injury includes a relatively narrow spectrum of alterations that, regardless of the cause, are represented by phlogosis, oxidative stress and necrosis. The combination of these alterations mainly results in three radiological findings: vascular alterations, structural changes and metabolic function reduction. Chemotherapy has changed in recent decades in terms of the drugs, protocols and duration, allowing patients a longer life expectancy. As a consequence, we are currently observing an increase in chemotherapy-associated liver injury patterns once considered unusual. Recognizing this form of damage in an early stage is crucial for reconsidering the therapy regimen and thus avoiding severe complications. In this frontier article, we analyze the role of imaging in detecting some of these pathological patterns, such as pseudocirrhosis, “yellow liver” due to chemotherapy-associated steatosis-steatohepatitis, and “blue liver”, including sinusoidal obstruction syndrome, veno-occlusive disease and peliosis.

Keywords: Hepatic damage, Yellow liver, Chemotherapy-associated steatohepatitis, Blue liver, Sinusoidal obstruction syndrome, Veno-occlusive disease, Peliosis, Pseudocirrhosis

Core Tip: Chemotherapy-induced hepatic damage represents an increasingly frequent condition observed in oncology patients: recent pharmacological innovations and specific and longer therapies have led to longer life expectancy and, inevitably, to an increase in systemic side effects and organ damage, primarily in the liver because of its detoxifying function. Even for experienced radiologists, the assessment of radiological patterns associated with liver injury derived from chemotherapy can sometimes be challenging. Our aim is to summarize useful ways to recognize, understand and monitor the evolution of these forms of hepatic damage to support clinicians in decision making.